Nanobody-Based Diagnostics Global Market Report 2026

Nanobody-based diagnostics use single-domain antibodies derived from camelids, which are smaller, highly stable, and extremely specific compared to traditional antibodies. These nanobodies efficiently bind to target molecules, allowing sensitive and rapid detection of biomolecules or pathogens, and are widely applied in diagnostic assays and imaging.

The key technologies of nanobody-based diagnostics include immunoassays, molecular diagnostics, biosensor-based detection, and fluorescence and imaging diagnostics. Immunoassays are laboratory techniques that detect or quantify specific molecules, such as proteins or hormones, using antibodies or antigens. Product types include reagents, kits, instruments, and other variants. Applications cover infectious diseases, oncology, autoimmune disorders, cardiovascular diseases, and other areas, with end users including hospitals and clinics, diagnostic laboratories, research institutes, and other sectors.

Tariffs on imported laboratory reagents, diagnostic instruments, and specialty biomolecule production materials are impacting the nanobody-based diagnostics market by increasing manufacturing and procurement costs, particularly affecting reagents, kits, and biosensor-based detection segments. Regions such as North America and Europe that rely on cross-border supply chains for advanced laboratory components are most affected. Higher costs may slow adoption in hospitals and diagnostic laboratories; however, tariffs are also encouraging domestic production of recombinant nanobodies and localized assay kit manufacturing, strengthening regional supply resilience and innovation capacity.

The nanobody-based diagnostics market research report is one of a series of new reports from The Business Research Company that provides nanobody-based diagnostics market statistics, including nanobody-based diagnostics industry global market size, regional shares, competitors with a nanobody-based diagnostics market share, detailed nanobody-based diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the nanobody-based diagnostics industry. This nanobody-based diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nanobody-based diagnostics market size has grown rapidly in recent years. It will grow from $1.13 billion in 2025 to $1.27 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to advancements in antibody engineering technologies, increasing prevalence of infectious diseases, growth in cancer diagnostics demand, rising research funding in immunodiagnostics, expansion of rapid diagnostic testing platforms.

The nanobody-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to growing demand for precision diagnostics, increasing integration of AI-based assay analysis tools, rising adoption of microfluidic biosensor systems, expansion of decentralized diagnostic testing, increasing focus on early disease detection biomarkers. Major trends in the forecast period include increasing adoption of lateral flow nanobody assays, rising demand for high-affinity single-domain antibody reagents, growing integration of nanobodies in point-of-care diagnostics, expansion of multiplexed biomarker detection platforms, rising use of nanobody-based imaging in disease monitoring.

The rising prevalence of infectious diseases is anticipated to drive the expansion of the nanobody-based diagnostics market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted from person to person or through contact with contaminated environments. The increase in infectious disease prevalence is largely due to closer human interactions, which facilitate the spread of pathogens within communities. Nanobody-based diagnostics offer rapid, highly specific, and sensitive detection of infectious agents, allowing for early diagnosis and timely treatment, thereby helping to control disease spread and enhance patient outcomes. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Thus, the growing prevalence of infectious diseases is supporting the growth of the nanobody-based diagnostics market.

Key companies operating in the nanobody-based diagnostics market are focusing on developing innovative solutions such as, advanced nanobody platforms to improve the accuracy and speed of disease detection. Advanced nanobody platforms use small, single-domain antibodies that are highly specific and stable, enabling faster tissue penetration, improved targeting of disease biomarkers, and enhanced diagnostic and therapeutic effectiveness compared to conventional antibodies. For example, in September 2025, Cyclotek Pty Ltd, an Australia-based radiopharmaceutical company, was awarded a CRC-P Round 16 grant by the Australian Government to advance a nanobody-based theranostic platform for cancer. In collaboration with the University of Melbourne, Revela Bio Inc., and several local SMEs, the project focuses on developing targeted diagnostics and therapeutics that leverage nanobodies against the Fibroblast Activation Protein (FAP), a biomarker highly expressed in aggressive cancers such as lung, pancreatic, and ovarian cancer. Nanobodies combine the precision targeting of antibodies with the pharmacokinetics of small molecules, making them ideal for both diagnostic imaging and therapeutic applications. The initiative aims to develop advanced radiolabelling chemistry, conduct pre-clinical evaluations, and progress to first-in-human clinical trials, positioning Cyclotek Pty Ltd to scale and commercialize this innovative platform across Australia, New Zealand, and the broader Asia-Pacific region.

The rising healthcare investments are expected to further propel the expansion of the nanobody-based diagnostics market. Healthcare investments involve the allocation of financial resources by governments, organizations, and healthcare providers to enhance medical infrastructure, services, technology, and overall healthcare delivery. These investments are increasing due to heightened demand for advanced medical services and modern technologies that improve patient care and health outcomes. Such investments facilitate the development and adoption of nanobody-based diagnostics by funding advanced research, upgrading laboratory infrastructure, and enabling healthcare providers to implement cutting-edge diagnostic technologies for more accurate and timely disease detection. For instance, in January 2026, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that Medicare spending in 2024 grew by 7.8%, reaching $1,118.0 billion and accounting for 21% of total national health expenditures (NHE), while Medicaid spending increased by 6.6% to $931.7 billion, representing 18% of total NHE. Therefore, increasing healthcare investments are contributing to the growth of the nanobody-based diagnostics market.

Major companies operating in the nanobody-based diagnostics market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Biocytogen LLC, Sino Biological Inc., Abzena plc, NanoTemper Technologies GmbH, RayBiotech Inc., Proteintech Group Inc., Creative Biolabs Inc., Isogenica Ltd., Beroni Group Limited, Immudex ApS, Cyclotek Pty Ltd, NanoTag Biotechnologies GmbH.

North America was the largest region in the nanobody-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanobody-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nanobody-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nanobody-based diagnostics market consists of revenues earned by entities by providing services such as biomarker detection, assay development, immunodiagnostic testing, molecular diagnostics support, and research-grade diagnostic solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanobody-based diagnostics market includes sales of nanobody-based assay kits, biosensors, diagnostic reagents, imaging probes, and targeted detection platforms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nanobody-Based Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nanobody-based diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nanobody-based diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nanobody-based diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Technology: Immunoassays; Molecular Diagnostics; Biosensor-Based Detection; Fluorescence And Imaging Diagnostics
• 2) By Product Type: Reagents; Kits; Instruments; Other Product Types
• 3) By Application: Infectious Diseases; Oncology; Autoimmune Disorders; Cardiovascular Diseases; Other Applications
• 4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
• Subsegments:
• 1) By Immunoassays: Enzyme Linked Immunosorbent Assay; Western Blotting; Lateral Flow Assay; Radioimmunoassay
• 2) By Molecular Diagnostics: Polymerase Chain Reaction Based Assays; Nucleic Acid Hybridization; Next Generation Sequencing; Isothermal Amplification Techniques
• 3) By Biosensor Based Detection: Electrochemical Biosensors; Optical Biosensors; Piezoelectric Biosensors; Microfluidic Biosensors
• 4) By Fluorescence and Imaging Diagnostics: Fluorescence Microscopy; Flow Cytometry; Fluorescence In Situ Hybridization; Molecular Imaging Techniques
• Companies Mentioned: Sanofi S.A.; Thermo Fisher Scientific Inc.; Merck KGaA; Agilent Technologies Inc.; PerkinElmer Inc.; Bruker Corporation; Bio-Rad Laboratories Inc.; GenScript Biotech Corporation; Biocytogen LLC; Sino Biological Inc.; Abzena plc; NanoTemper Technologies GmbH; RayBiotech Inc.; Proteintech Group Inc.; Creative Biolabs Inc.; Isogenica Ltd.; Beroni Group Limited; Immudex ApS; Cyclotek Pty Ltd; NanoTag Biotechnologies GmbH.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.